Symptom burden among head and neck cancer patients in the first year after diagnosis: Association with primary treatment modality

Allen-Ayodabo, Catherine; Eskander, Antoine; Davis, Laura; Zhao, Haoyu; Mahar, Alyson; Karam, Irene; Singh, Simron; Gupta, Vaibhav; Bubis, Lev D.; Moody, Lesley; Barbera, Lisa; Coburn, Natalie

doi:10.1016/j.oraloncology.2019.09.026

Cited by 37 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pain is one of the most problematic acute and late toxicities of radiation therapy for patients with head and neck cancer (HNC) 1‐4 . Although there are numerous etiologies for this pain, radiation mucositis has garnered particular attention due to its immediate and profound impact on critical functions such as swallowing, speaking, and handling secretions 5,6 .…”

Section: Introductionmentioning

confidence: 99%

Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation

et al. 2020

View full text Add to dashboard Cite

Background: Radiation for patients with head and neck cancer (HNC) is associated with painful mucositis that impacts the delivery of treatment and contributes to high symptom burden. Methods: This was a prospective, randomized pilot trial. Eligible patients received primary or adjuvant chemoradiation. Patients were randomized to usual care vs usual care plus gabapentin titrated to drug tolerance during radiation. Patients completed a symptom survey at baseline and weekly during therapy. Results: Seventy-nine patients were enrolled in the study (38 control, 41 treatment). At interim analysis, gabapentin use resulted in a decrease in pain (P = .004), with the biggest decreases being in the latter weeks of therapy. By week 7, the median pain score in the treatment group was below the 0.25 quantile of the control group. Conclusion: Prophylactic use of gabapentin during chemoradiation for HNC patients resulted in a decrease in pain, neurosensory symptoms, and general systemic symptoms.

show abstract

Section: Introductionmentioning

confidence: 99%

Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The short-term symptom burden was highest in the early post-treatment period (4-10 weeks) with non-signi cant differences between groups [11]. A cohort study con rms that patients with HNC have a high symptom burden which peaks during treatment and need for symptom management during this period in the patient's trajectory [38]. This may indicate the need to look more in-depth at challenges surgically treated patients face in the short-term post-operative phase.…”

Section: Discussionmentioning

confidence: 91%

Needs assessment in patients surgically treated for head and neck cancer—a randomized controlled trial

Mortensen

Wessel

Rogers

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Females mice exhibit greater nociceptive behavior in the 4NQO model (Scheff et al 2018). Women with oral SCC report greater pain than men (Reyes-Gibby et al 2014; Allen-Ayodabo et al 2019). Future studies are required to validate our observations and investigate sex as a biologic variable.…”

Section: Discussionmentioning

confidence: 98%

“…The 4NQO model rarely yields metastatic lesions (Li et al 2013). A high rate of metastasis has been reported in mice genetically engineered to overexpress Pik3ca (Du et al 2016), suggesting that cancer associated nociception and metastasis could be studied in such genetically engineered mice (Allen-Ayodabo et al 2019) or in xenograft mouse models (Judd et al 2012; Shirako et al 2015).…”

Section: Discussionmentioning

confidence: 99%

The Histopathology of Oral Cancer Pain in a Mouse Model and a Human Cohort

et al. 2020

View full text Add to dashboard Cite

Oral cancer patients often have severe, chronic, and mechanically induced pain at the site of the primary cancer. Oral cancer pain is initiated and maintained in the cancer microenvironment and attributed to release of mediators that sensitize primary sensory nerves. This study was designed to investigate the histopathology associated with painful oral cancers in a preclinical model. The relationship of pain scores with pathologic variables was also investigated in a cohort of 72 oral cancer patients. Wild-type mice were exposed to the carcinogen, 4-nitroquinoline 1-oxide (4NQO). Nociceptive (pain) behavior was measured with the dolognawmeter, an operant device and assay for measuring functional and mechanical allodynia. Lesions developed on the tongues and esophagi of the 4NQO-treated animals and included hyperkeratoses, papillomas, dysplasias, and cancers. Papillomas included lesions with benign and dysplastic pathological features. Two histologic subtypes of squamous cell carcinomas (SCCs) were identified—SCCs with exophytic and invasive components associated with papillary lesions (pSCCs) and invasive SCCs without exophytic histology (iSCCs). Only the pSCC subtype of tongue cancer was associated with nociceptive behavior. Increased tumor size was associated with greater nociceptive behavior in the mouse model and more pain experienced by oral cancer patients. In addition, depth of invasion was associated with patient-reported pain. The pSCC histology identifies 4NQO-induced tongue cancers that are expected to be enriched for expression and release of nociceptive mediators.

show abstract

Symptom burden among head and neck cancer patients in the first year after diagnosis: Association with primary treatment modality

Cited by 37 publications

References 26 publications

Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation

Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation

Needs assessment in patients surgically treated for head and neck cancer—a randomized controlled trial

The Histopathology of Oral Cancer Pain in a Mouse Model and a Human Cohort

Contact Info

Product

Resources

About